Why do medical devices need different vulnerability governance than enterprise IT?

Why This Matters for Security Teams

Medical device vulnerability governance is not a simple extension of enterprise patch management. A device can support critical therapy, monitoring, or imaging, so the security decision has to consider patient safety, uptime, device lifecycle, and whether the vendor has validated a fix for clinical use. The same vulnerability that is routine on a laptop may require staged rollout, compensating controls, or formal acceptance on a device in active care. Current guidance from the NIST Cybersecurity Framework 2.0 reinforces that governance must be risk-based and operationally integrated, not treated as an isolated IT task.

Security teams often get this wrong by applying enterprise patch SLAs to environments that cannot tolerate unscheduled downtime or unsupported firmware changes. That creates either unsafe haste or paralysis, both of which increase exposure. The better model is to classify devices by clinical criticality, connectivity, and compensating control maturity before deciding whether remediation is immediate, deferred, or replaced through isolation and monitoring. In practice, many security teams encounter the true governance gap only after a clinical system is already in service and a fix must be weighed against patient impact, rather than through intentional pre-deployment risk review.

How It Works in Practice

Effective medical device vulnerability governance starts with asset visibility and ownership. Teams need to know the device model, software version, support status, clinical function, and whether the device is directly exposed, network-restricted, or dependent on a hospital platform. That inventory then feeds a decision process that combines technical severity with operational context, because a high-scoring vulnerability may still be managed safely through segmentation, strict access control, or monitored compensating measures while a lower-scoring flaw may be more urgent if it affects a safety-critical workflow.

Practitioners usually build governance around four steps:

• Identify the device, vendor, and maintenance pathway, including whether the manufacturer supports a patch or workaround.
• Assess clinical impact, including whether the device is in continuous use, intermittent use, or offline between procedures.
• Choose remediation timing, such as immediate patching, maintenance-window patching, isolation, or formal residual-risk acceptance.
• Verify controls through logging, segmentation, and incident response runbooks aligned to device behavior.

That process should be paired with threat intelligence and vendor advisories. Resources such as CISA cyber threat advisories and the ENISA Threat Landscape help teams understand exploitation trends and prioritise exposure, but they do not replace device-specific clinical review. Where possible, governance should also reflect baseline hardening and control mapping from CIS Controls v8, especially for inventory, secure configuration, and monitoring.

These controls tend to break down in environments with legacy devices that cannot be patched, have no vendor support, and sit on flat networks shared with administrative systems.

Common Variations and Edge Cases

Tighter vulnerability governance often increases operational overhead, requiring organisations to balance patient safety and compliance against speed of remediation. That tradeoff becomes sharper in mixed estates where new connected devices coexist with older systems that were never designed for modern update workflows. Best practice is evolving, and there is no universal standard for how much residual risk is acceptable when a fix could disrupt a clinical process.

One common edge case is a device that is technically vulnerable but clinically isolated. In that situation, the governance decision may favour containment, network restrictions, and enhanced monitoring over immediate patching. Another is a shared platform supporting multiple devices, where one software change affects several clinical services at once. Here, change control becomes a safety function, not just an IT process. Organisations should also account for procurement and lifecycle governance, because unsupported devices create recurring exceptions that cannot be managed indefinitely.

This is also where the identity intersection matters. Medical devices often rely on service accounts, embedded credentials, remote vendor access, and connected management tools. If those identities are not governed tightly, vulnerability handling becomes weaker regardless of patching speed. In practice, remediation stalls when clinical engineering, IT, and vendors do not share a documented approval path for who can change what, when, and under which risk acceptance criteria.

Related resources from NHI Mgmt Group

• Why do connected devices create a different identity governance problem than users?
• Why do legacy medical devices create a different risk model from ordinary IT assets?
• What governance controls should every enterprise put in place before deploying AI agents?
• What are MCP Authorisation Extensions and why do they matter for enterprise governance?